D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

• Male or female

• Age 18-65 years

• Diagnosis of schizophrenia or schizoaffective disorder, depressed type

• Stable dose of antipsychotic for at least 4 weeks

• Able to provide informed consent

• Able to complete a cognitive battery

• Able to perform the cognitive remediation exercises

Exclusion Criteria:

• Current treatment with clozapine

• Dementia

• Seizure disorder

• Unstable medical illness

• Renal insufficiency measured as eGFR >60mg/dL/min

• Active substance abuse: positive urine toxic screen

• Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.